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Systematic analysis of
hematopoietic gene expression
profiles for prognostic prediction in
acute myeloid leukemia
Frederick S. Varn1, Erik H. Andrews1 & Chao Cheng1,2,3
Acute myeloid leukemia (AML) is a hematopoietic disorder initiated by the leukemogenic
transformation of myeloid cells into leukemia stem cells (LSCs). Preexisting gene expression
programs in LSCs can be used to assess their transcriptional similarity to hematopoietic cell types.
While this relationship has previously been examined on a small scale, an analysis that systematically
investigates this relationship throughout the hematopoietic hierarchy has yet to be implemented. We
developed an integrative approach to assess the similarity between AML patient tumor profiles and
a collection of 232 murine hematopoietic gene expression profiles compiled by the Immunological
Genome Project. The resulting lineage similarity scores (LSS) were correlated with patient survival
to assess the relationship between hematopoietic similarity and patient prognosis. This analysis
demonstrated that patient tumor similarity to immature hematopoietic cell types correlated with
poor survival. As a proof of concept, we highlighted one cell type identified by our analysis, the
short-term reconstituting stem cell, whose LSSs were significantly correlated with patient prognosis
across multiple datasets, and showed distinct patterns in patients stratified by traditional clinical
variables. Finally, we validated our use of murine profiles by demonstrating similar results when
applying our method to human profiles.

Hematopoiesis is the developmental program that gives rise to the cellular components of blood. This
process is hierarchical, with multipotent hematopoietic stem cells (HSCs) generating myeloid and lymphoid progenitor cells, which then generate more differentiated cell types1. Mutations in hematopoietic
cells can upset this process, resulting in a variety of blood maladies, including cancer. Acute myeloid
leukemia (AML) is one such cancer, characterized by the accumulation of aberrant primitive myeloid
cells2,3. These cells have a limited proliferative capability, suggesting the existence of an underlying
sub-population of proliferative cells that maintain the leukemia. Evidence for the existence of these leukemia stem cells (LSCs) was first reported when a population of human CD34+CD38− AML patient cells
successfully initiated AML in a SCID mouse xenograft model4–6. A follow-up study showed that LSCs
are hierarchically organized, with varying self-renewal capabilities7. Additional reports have suggested
that AML-initiating cells are not limited to the CD34+CD38− cell population and are found in the
CD34+CD38+ and CD34−CD38− cell populations as well8,9. Taken together, these studies portray AML
as a heterogeneous disease that can be initiated and maintained through a variety of cell types.
The heterogeneity of AML has made accurately predicting patient prognosis difficult. Most commonly, cytogenetic analysis is used to subtype patients by karyotype10. However, nearly 50% of AML
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cases have a normal karyotype, leaving a large fraction of heterogeneous samples without further classification. For these patients, molecular mutations, such as FLT3 internal tandem duplications, MLL
partial tandem duplications, mutations in the NPM1 and CEBPA genes, and heightened expression of
the BAALC and ERG genes are used as prognostic indicators11. Gene expression microarray analyses
have led to additional classification schemes that can further stratify patients for prognostic purposes
and increase the resolution by which we can study their molecular pathology. Multiple studies have
clustered AML samples using gene expression profiles, revealing different molecular subgroups defined
by previously identified cytogenetic abnormalities12–18. Another study has drawn upon the stem cell-like
nature of LSCs to create a robust, prognostic gene expression signature19. Patients with high expression
of this signature’s genes tend to have an adverse outcome, supporting the LSC hypothesis and suggesting
that LSC activity may be driving AML severity. This idea was furthered by work showing that HSCs and
LSCs share a core transcriptional program that imparts stem cell properties, including self-renewal and
differentiated progeny production20.
Although these studies have improved prognostic accuracy, they have limitations. Hematopoiesis is
extremely complex, involving a vast number of cells of varying maturity that express a wide array of
cell-surface markers1. Understanding the dominant hematopoietic programs in a patient’s leukemia may
elucidate features that can be used to improve disease characterization. Recently, a group has reported
that, in MLL-rearranged AML, the LSC shares a common transcriptional signature similar with its cell
of origin. This group compared AML arising from HSCs to AML arising from granulocyte-macrophage
progenitors (GMPs) and found that HSC-derived AML had an expedited onset and a greater resistance
to chemotherapy21. Taking this idea further, a systematic analysis that correlates AML tumor profiles
across profiles from cells throughout the hematopoietic hierarchy could offer a highly specific assessment
of the molecular makeup of a patient’s leukemia, including any hematopoietic programs the cell may
have inherited from it’s origin cell. While human hematopoietic gene expression profiles are a useful
tool to use in this analysis, murine hematopoietic profiles can serve as a proxy for many human profiles22,23 and offer several additional advantages. Using mice allows for hematopoietic gene expression
profiling to be carefully controlled to diminish noise and batch variability between studies. Additionally,
mice can be easily subjected to genetic and environmental perturbations enabling more comprehensive
profiling studies of hematopoiesis. One such study has been performed by the Immunological Genome
Project Consortium and has resulted in a series of 232 murine hematopoietic cell lineage gene expression
profiles24.
Here, we extend our previously developed BASE (binding association with sorted expression) algorithm25 to systematically investigate the similarity between human AML gene expression data and the 232
murine transcription profiles compiled by the Immunological Genome Project. The BASE algorithm was
originally developed to infer transcription factor activity from gene expression profiles using ChIP-chip
and ChIP-seq data. We have recently shown that it can be used to calculate the activity of binary gene
sets in breast cancer samples26 and now, by substituting binding affinity data with hematopoietic gene
expression profiles, we demonstrate its utility in calculating the activity of hematopoietic transcription
programs in patient AML samples. This process will provide information about the molecular makeup of
a patient’s AML, allowing us to perform follow-up analyses to make prognostic predictions and further
characterize the cancer.
We begin by using BASE to calculate the lineage similarity score (LSS), a summary statistic that
encapsulates the similarity between patient AML gene expression data and the murine hematopoietic
cell lineage expression profiles generated by the Immunological Genome Project. We then apply Cox
proportional-hazards (PH) models to identify the hematopoietic cell types whose LSSs most closely
associate with patient survival. We find that patients whose AML profiles most resemble immature
hematopoietic cell profiles tend to have diminished survival time. As a proof of concept, we highlight a
short-term reconstituting stem cell gene expression profile that is especially predictive of patient prognosis. We demonstrate that this profile aligns with traditional AML classification schemes including
French-American-British (FAB) subtyping and FLT3 mutation status, and is also predictive of induction
therapy response. We apply this profile to three independent AML patient datasets and show that it
remains predictive across all of them. Finally, we validate our findings using murine profiles by comparing their prognostic performance with that of their analogous human cell counterparts.

Results

Overview.

Figure 1A provides a schematic of our analysis. Murine hematopoietic cell lineage profiles
for 232 cell types from the Immunological Genome Project24 were combined with the AML patient gene
expression dataset generated by Bullinger et al. (GSE 425)27 using BASE to generate a matrix of LSSs for
each patient across all 232 cell types. A high LSS indicated high concordance between a patient’s and a
cell type’s gene expression profile, while a low LSS indicated the opposite (Fig. 1B). Univariate survival
analyses using Cox PH regression were conducted for each cell type’s LSSs to identify cell types with
AML prognostic significance. Multivariate Cox PH survival analyses to correct for clinicopathological
variables were then conducted on these cell types for further analysis.

Identification of survival-associated hematopoietic cell profiles.

To identify patterns of hematopoietic cell types that correlate with overall AML patient survival, hierarchical clustering and heatmap
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Figure 1. Overview of workflow. (a) Murine hematopoietic cell expression profiles were downloaded
from the Immunological Genome Project and compared against patient gene expression profiles from
an AML dataset of interest using the BASE algorithm. This resulted in a lineage similarity score (LSS)
that reflects gene expression concordance between a given hematopoietic cell type and a given patient.
The resulting patient LSSs were then used as covariates in a Cox proportional hazards model. Cell types
that were significantly associated with patient survival were explored in more detail. (b) For each murine
hematopoietic cell profile, genes are ranked from high to low based on their expression values. These
weights are then assigned to a list of genes ranked by patient gene expression profiles. LSSup is determined
based on concordance between hematopoietic up-regulated weights and patient rank, with a more positive
value representing higher concordance. LSSdn is determined based on concordance with the down-regulated
weights and patient rank, with a more negative value representing higher concordance. Dotted lines
represent 10*mean(weight) over a rolling window of 1000 genes. The LSSdn is then subtracted from the
LSSup to obtain the final LSS, which represents the similarity between patient and hematopoietic cell gene
expression profiles. Patients 1, 2, and 3 are examples of a high, intermediate, and low LSS, respectively.

generation using the patient LSSs for each cell type was performed (Fig. 2A). Most of the 232 murine
cell types did not show any concordance in gene expression with AML patients. Notably, the lowest LSSs
were found in a cluster enriched in differentiated myeloid and stromal cell types, indicating high discordance between AML patient profiles and cells of these types (Fig. 2A, bracket). However, there were 42
cell types that had an LSS >  0 in at least half of the samples, showing that many murine hematopoietic
lineages do share biological properties with human leukemias, despite the species barrier.
To examine whether this similarity had a clinical application in AML, we cut the hierarchical clustering tree at a depth that generated four clusters of samples with low intra-cluster LSS variability but
high inter-cluster LSS variability. We then compared the survival distributions of each cluster using a
log-rank test (P =  0.08) (Fig. 2B). While the survival distributions of each cluster were not significantly
different from each other, we decided to investigate further by looking at the survival distributions of
the individual cell type LSSs.
Univariate Cox PH models were used to measure the correlation between LSS as a continuous variable
and patient survival time for each cell type (Supplementary Table S1). Figure 3A shows the distribution
of the adjusted P and hazard ratios (HR) of each cell type’s result. Only two cell types yielded adjusted
P <  0.05, the CD150−CD48− short-term reconstituting stem cell (STRSC) derived from bone marrow
(adjusted P =  0.01, HR =  1.17, 95% CI =  1.08–1.25) and the CD44+NK1.1+ thymus invariant iNKT precursor cell (adjusted P =  0.03, HR =  0.81, 95% CI =  0.72–0.91). Figure 3B shows their LSS distributions.
The STRSC LSSs were primarily positive, with 111/116 samples having a positive LSS, while all 116
samples had negative CD44+NK1.1+ thymus invariant iNKT precursor cell LSSs. Because we were primarily interested in the survival distribution of leukemias that share expression profiles with cell types,
we decided to examine the STRSC profile in more detail.
Kaplan-Meier estimators were fitted to two groups of samples stratified into high and low LSS groups
(Fig. 3C). A log-rank test revealed that the patients in the high group had significantly shorter survival
times than the patients in the low group (P =  6e-4). This result was robust to a multivariate Cox PH
model correction for age, FAB subtype, FLT3 mutation status, CALGB-defined cytogenetic risk category,
and history of preceding malignancy (P =  0.03, HR =  1.12, 95% CI =  1.01–1.23) (Supplementary Table
S2; Fig. 3D). Taken together, this suggested that patients whose leukemias’ genetic profiles more closely
reflected the genetic profile of the STRSC tended to die at a faster rate than patients with more dissimilar
profiles.
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Figure 2. Exploratory analysis of Immunological Genome Project LSSs. (a) Heatmap showing the pattern
of 232 LSSs across the 116 samples from the Bullinger dataset. Each column represents one patient’s LSS
profile for each of the 232 murine hematopoietic cell types from the Immunological Genome Project. Green
is indicative of a lower (less similar) LSS while red is indicative of a higher (more similar) LSS. Patients
tended to have lower LSSs in more differentiated cell types (bracket). Patient clusters were chosen based
on patient location in the heatmap dendrogram (sidebar). (b) Kaplan-Meier plot depicting the survival
probability over time for each cluster. Vertical hash marks indicate points of censored data. The four clusters
did not show a significant difference in survival time (p >  0.05).

Cell lineage similarity scores and survival time.

To look at whether this effect was localized to
the STRSC profile, we relaxed the cutoff of our analysis and examined all lineages that were correlated
with patient survival at an unadjusted P <  0.05 threshold. To identify cell types that shared similar characteristics with the STRSC profile, we separated the significant cell types into a HR >  1 and a HR <  1
group. Strikingly, we found that 9/11 cell types in the HR >  1 group were classified as stem cells by the
Immunological Genome Project. The two remaining lineages were both located early in the T cell development pathway28. We highlight two examples in this group, the CD150+CD48− long-term reconstituting stem cell (LTRSC) derived from fetal liver and the CD150−CD48− STRSC derived from fetal liver
(Fig. 4, top). When samples were stratified into high and low LSS groups for each lineage, the samples
with higher LSSs had significantly worse survival than those with lower LSSs (P =  3e-3 and 3e-3, respectively, log-rank test).
In contrast, gene expression profiles that yielded a HR <  1 tended to be from more differentiated cell
types. This group included many different cell types, including dendritic cells (DC), monocytes, natural
killer cells, active and inactive α β T cells, and γ δ T cells. Notably, none of the cells in this group were
stem cells. When samples were stratified by LSS for two examples from this group, the Vg5+ intestinal intraepithelial lymphocyte (i-IEL) and the lung CD11b+ DC, the samples with higher LSSs had
significantly better survival than those with lower LSSs (P =  3e-3 and P =  0.02, respectively, log-rank
test) (Fig. 4, bottom). As a negative control to these analyses, we examined the association between
patient survival and stromal cell LSS, as these scores were uniformly distributed across samples (Fig. 2A,
bracket). As expected, none of these cell types were significantly associated with patient survival (P >  0.1,
Cox PH, Supplementary Table S1).

Association of STRSC LSSs with clinical variables. The FAB subtype system uses the percentage

and morphology of myeloblasts and erythroblasts in a patient’s blood to subtype the patient’s disease.
The system classifies AML into one of eight subtypes, M0 through M7. The M0 through M5 subtypes
have high percentages of immature myeloblasts, with M0 myeloblasts appearing the least mature and
M5 myeloblasts appearing the most mature histologically, while the M6 and M7 subtypes have high
percentages of immature erythrocytes and megakaryocytes, respectively29. The leukemia samples in this
dataset included 3 M0, 13 M1, 25 M2, 12 M3, 35 M4, and 15 M5. We examined the STRSC LSS distributions of the M0-M5 subtypes (Fig. 5A). As can be seen, the LSSs demonstrated a decreasing trend from
M1 to M5, suggesting that that the mouse STRSC LSS reflected the degree of differentiation in human
AML. In support of this, a significant difference in LSS was observed between the subtypes (P =  0.02,
Kruskal-Wallis). Furthermore, dichotomizing patient samples into two groups on the basis of cellular
maturity, with the immature group made up of the M0 through M2 subtypes and the mature group
Scientific Reports | 5:16987 | DOI: 10.1038/srep16987
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Figure 3. Survival analysis of the short-term reconstituting stem cell LSS. (a) Distribution of the hazard
ratios and adjusted p-values derived from univariate Cox proportional-hazards models that included murine
hematopoietic cell type LSSs as the variables. Each point corresponds to a different cell type, with red points
corresponding to cell types with an adjusted p-value <  0.05 and blue points corresponding to cell types
with an adjusted p-value >  0.05. The two red dots correspond to the short-term reconstituting stem cell
(STRSC) and thymus invariant iNKT precursor CD44+NK1.1+ (TIIP). (b) Density plot of the LSSs for the
two cell types significantly associated with survival in the Bullinger dataset. The STRSC is represented by
a cyan curve and the TIIP is represented by a magenta curve. (c) Kaplan-Meier plot depicting the survival
probability over time for samples with a high (red curve) and low (green curve) STRSC LSS. Vertical hash
marks indicate points of censored data. (d) In a multivariate Cox proportional-hazards model, the STRSC
LSS is significantly predictive of patient survival even after adjusting for traditional clinical factors. Bars
represent log(hazard ratio) 95% confidence interval. Red dotted line indicates where the log10(hazard
ratio) =  0.

consisting of the M3 through M5 subtypes, revealed that samples from more immature FAB subtypes
had significantly higher STRSC LSSs than samples from more mature FAB subtypes (P =  0.02, Wilcoxon
rank-sum test) (Fig. 5A). Though the M0 subtype was expected to have the highest STRSC LSS, the
low number of M0 samples may have been confounding this observation. Interestingly, we observed a
decreasing trend from M0 to M5 for LSSs from naïve CD8+ and CD4+ T cells that reside in the lymph
node (Supplementary Fig. S1). However, LSSs of these cell types were not associated with patient survival.
FLT3 is a receptor tyrosine kinase involved in the proliferation and development of hematopoietic
stem cells30. Mutations resulting in FLT3 activation have been found in about 30% of AML patients and
are correlated with poor prognosis30. Interestingly, samples with a mutated copy of FLT3 had significantly
higher STRSC LSSs than FLT3 wild type samples (P =  0.03, Wilcoxon rank-sum test, Fig. 5B). This result
indicated that there was a correlation between the mouse STRSC LSS and the mutation status of the
FLT3 gene.
Stratifying patients by remission status allowed us to test whether there was a correlation between
STRSC LSSs and the patient response to induction therapy27. There were four types of responses
observed: complete response to therapy (CR), relapse (REL), refractory disease (RD), and early death due
to treatment toxicity (ED). A significant difference in LSS was observed across the treatment outcomes
(P =  0.005, Kruskal-Wallis). Additionally, STRSC LSSs in CR samples were significantly lower than REL,
RD, and ED samples (P =  0.05, 0.001, and 0.05, respectively, Wilcoxon rank-sum test; Fig. 5C). These
Scientific Reports | 5:16987 | DOI: 10.1038/srep16987
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Figure 4. Survival analysis of different LSSs in AML patients. Kaplan-Meier plots depicting the survival
probability over time for samples with high (red curves) and low (green curves) LSSs for four different
cell types. Vertical hash marks indicate points of censored data. Hazard ratios are >  1 in the long-term
reconstituting stem cell from fetal liver and short-term reconstituting stem cell from fetal liver cell types,
indicating genetic similarity to these cell types has a deleterious effect on survival (top). Hazard ratios
are <  1 in i-IEL VG5+, activated and lung CD11b+ DC, indicating greater profile similarity to these cell
types is associated with increased survival time (bottom).

results suggested that the STRSC LSS could be a useful marker to predict the effectiveness of induction
therapy on a patient.

Application of the STRSC to other datasets. To confirm the findings from the Bullinger dataset,
we expanded our analysis to four additional independent datasets by Wilson et al. (willm-00119)31, Valk
et al. (GSE1159)15, Metzeler et al. (GSE12417)32, and the AML dataset generated by The Cancer Genome
Atlas (TCGA)33. For each dataset, patients were stratified into high and low groups based on their STRSC
LSS. This profile remained predictive of overall survival across the Wilson (P =  6e-5, log-rank test), Valk
(P =  2e-5, log-rank test), Metzeler (P =  0.02, log-rank test), and TCGA (P =  0.05, log-rank test) datasets
(Fig. 6). The reproducibility of the STRSC profile validated our findings in the Bullinger dataset and
indicated that the results from our analysis were generalizable across multiple datasets.
Comparison of murine hematopoietic profiles to human hematopoietic profiles. To fur-

ther validate our results from using murine lineages, we examined the predictive ability of analogous
human lineage profiles from both the GSE24006 dataset by Gentles et al.19 and the GSE24759 dataset by Novershtern et al.34 The Gentles et al. dataset included transcriptional profiles from seven different lineages: AML LSCs, AML leukemia progenitor cells, AML blasts, normal hematopoietic stem
cells (HSCs), normal multipotent progenitors (MPPs), normal common myeloid progenitors, normal
granulocyte-monocyte progenitors, and megakaryocyte-erythrocyte progenitors. We calculated LSSs for
the seven cell types for each patient and then correlated the LSSs with survival using a univariate Cox
proportional-hazards model, just as we did for the mouse data (Supplementary Table S3). Both the
human HSC and MPP expression profiles were significantly correlated with patient survival (P =  0.001,
HR =  1.04, 95% CI =  1.02–1.07, and P =  0.006, HR =  1.02, 95% CI =  1.01–1.04, respectively, Cox PH).
Figure 7A shows the survival distributions of samples from the high and low HSC LSS groups (P =  0.002,
log-rank test). This analysis is repeated with the MPP LSSs in Fig. 7B (P =  0.005, log-rank test).
Scientific Reports | 5:16987 | DOI: 10.1038/srep16987
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The Novershtern et al. dataset detailed a comprehensive gene expression analysis of 38 different cell
types involved in human hematopoiesis. To examine the analogous cell types’ association with patient
survival, we repeated the analysis we performed on the Gentles et al. data, and examined the results in
the relevant dedifferentiated cell populations (Supplementary Table S4). Three of the four dedifferentiated
cell types were significantly associated with poor survival, the CD133+CD34 diminished HSCs (P =  0.03,
HR =  1.04, 95% CI =  1.00–1.08, Cox PH), CD38–CD34+ HSCs (P =  0.02, HR =  1.03, 95% CI =  1.01–1.06,
Cox PH), and megakaryocyte erythroid progenitors (P =  0.005, HR =  1.09, CI =  1.03–1.16, Cox PH). The
fourth dedifferentiated cell type, the common myeloid progenitor, was not significantly associated with
patient survival (P >  0.05, Cox PH), matching our findings using the murine data and the dataset by
Gentles et al.
In both cases, these findings were in agreement with our results using murine lineage profiles, as
human HSC lineages were analogous to the mouse STRSC line23. Additionally, the findings in both
datasets globally showed a pattern consistent with our findings using the univariate Cox model (see
Supplementary Table S1), with LSSs from dedifferentiated murine cell types being predictive of patient
survival. The reproducibility of our findings in both mouse and humans suggested that the murine lineage profiles generated by the Immunological Genome Project were useful proxies for the analogous
human immune cell lineages and had potential clinical applications in the context of human AML.

Discussion

AML is a heterogeneous disease that presents prognostic challenges. Beyond differences in cytogenetics
and specific gene mutations, it is increasingly understood that a major source of AML’s variation in
survival is a result of gene expression programs inherited from the origin cell of an LSC. This suggests
that a better understanding of hematopoietic transcriptional profiles in the context of AML would provide additional insight into AML patient survival outcome. This is the general method we pursued here,
utilizing murine hematopoietic transcription profiles for their high quality, high resolution, and similarity to human hematopoietic profiles. Our integrative analysis compared the gene expression profiles of
AML samples to the gene expression profiles of 232 murine hematopoietic cell lineages, quantifying the
degree of concordance between the AML samples and cell lineages using the Lineage Similarity Score
(LSS). These scores allowed us to assess the activity of hematopoietic programs in human AML at a
Scientific Reports | 5:16987 | DOI: 10.1038/srep16987

7

www.nature.com/scientificreports/
Wilson

1.00

Valk

1.00

p = 6e−04
High (n=96)
Low (n=74)

0.75

Probability of survival

p = 2e−04

0.50

0.50

0.25

0.25

0.00

0

1000

2000

3000

0.00

4000

Metzeler

1.00

High (n=130)
Low (n=155)

0.75

0

50

100

150

TCGA

1.00

p = 0.05

p = 0.02
High (n=165)
Low (n=77)

0.75

0.50

0.25

0.25

0

500

1000

High (n=69)
Low (n=102)

0.75

0.50

0.00

200

0.00

1500

0

500

1000

1500

Survival time (days)

Figure 6. Survival analysis of the STRSC LSS across datasets. Across all datasets tested, patients with high
STRSC LSSs (red curve) had significantly shorter survival times than those with low STRSC LSSs (green
curve) (all P <  0.05, log-rank test). Vertical hash marks indicate points of censored data.
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Figure 7. Survival analysis of LSSs for human hematopoietic cell types. Kaplan-Meier plots depicting the
survival probability over time for samples with high (red curves) and low (green curves) LSSs for (a) human
hematopoietic stem cell (HSC) and (b) human multipotent progenitors (MPP). Vertical hash marks indicate
points of censored data. Both cell types were significantly associated with patient survival (P <  0.05, log-rank
test).

higher resolution than previously reported, and together with Cox PH models, examine each cell type’s
association with patient survival to identify which were survival prognostic. In agreement with previous
literature, transcriptional similarity to immature hematopoietic cells tended to be associated with shorter
survival times than transcriptional similarity to more differentiated cell types18–21.
To demonstrate the utility of our analysis, we highlighted the murine STRSC, the mouse analog of
the human HSC, as a prognostic indicator. By using the LSSs of this profile as a continuous variable to
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predict patient survival, we achieved a hazard ratio of 1.17, which compares favorably to the LSC signature developed by Gentles et al. (HR =  1.15)19. Our profile remained predictive even after correcting for
clinical and molecular pathological variables. The STRSC LSS was predictive across multiple datasets and
correlated with existing AML classification schemes, as significant differences were found between FAB
subtypes and FLT3 mutation groups. Furthermore, STRSC LSSs were correlated with response to induction therapy, with a lower LSS being characteristic of a complete response. Taken together, these data
showed that the LSS serves as a useful prognostic indicator that can be used to elucidate the underlying
gene expression program of a patient’s disease.
Correlating the large number of murine hematopoietic gene expression profiles to AML gene expression data yielded promising results for the future of AML classification and prognosis. The resolution
at which the murine hematopoietic system has been characterized to date has not yet been achieved in
humans. As such, future applications that use well-characterized murine genomic data may introduce
new avenues in disease characterization. The reproducible results we obtained by using murine hematopoietic cell profiles, and the similarity between our findings in murine and human profiles, demonstrate
that this data is applicable to human hematologic disease and may have further applications to areas of
computational genomics, and hematology and oncology in general. However, as important differences
still remain between murine and human hematopoietic lineages23, the method presented in this paper
will likely be improved further as our capacity to profile human hematopoietic cells catches up to our
murine profiling ability. Additionally, as more comprehensive datasets emerge that measure the full array
of cytogenetic abnormalities used to classify AML patients, a better understanding of the relationship
between hematopoietic transcriptional profiles and traditional prognostic indicators can be obtained.
This understanding could allow for further characterization of the underlying biology of AML, and aid
in personalized therapeutic research efforts.
Going forward, a major focus will be on better understanding the role of hematopoietic transcriptional profiles across other cancers that arise from the misregulation of hematopoiesis similarly to AML,
such as acute lymphoblastic leukemia (ALL). Our analysis can be readily applied to these cancers to identify prognostic hematopoietic profiles assuming there is gene expression data and survival information
present for a given cohort of patients. Similarly to AML, the results of this analysis in other hematopoietic diseases can aid in disease classification and subtyping, enabling personalized therapeutic approaches.
Additionally, the results obtained using this method can be easily compared across diseases, which can
help distinguish important similarities and differences about the hematopoietic state of each one.
In conclusion, we have developed an integrative analysis that correlates murine hematopoietic cell
gene expression profiles to AML patient data to measure the concordance of their gene expression programs. Using this technique, we have found, in agreement with other literature, that transcriptional
similarity to less differentiated hematopoietic cell types is indicative of a poor prognosis. We demonstrate this using the murine short-term reconstituting stem cell (STRSC), which is an especially effective
predictor of clinical outcome. This effect is pronounced in the unique LSS distribution that can be used
to define traditional AML subgroups and treatment response groups. Additionally, our findings using
murine profiles are reproducible in several datasets, and our methodology finds similar results when
substituting murine profiles for human ones. In summary, our analysis provides a method to assess the
role of hematopoietic transcriptional programs in AML patient survival. We are hopeful going forward
that the results of this analysis can eventually be translated into useful clinical practice.

Methods

Datasets. Five AML gene expression datasets were analyzed in this study. Each dataset chosen contained at least 100 samples and included clinical data and sufficient overall survival outcome information.
Three of the datasets were obtained from the Gene Expression Omnibus (GEO) database under the
accession numbers GSE425 (Bullinger et al., n =  116)27, GSE1159 (Valk et al., n =  285)15, and GSE12417
(Metzeler et al., n =  242)32. Acute myeloid leukemia (LAML) Level 3 gene expression data and clinical
information was downloaded from The Cancer Genome Atlas data portal (n =  171)33. The remaining
dataset was obtained from the NCI caArray database under the accession number willm-00119 (Wilson
et al., n =  170)31.
Mouse immune lineage gene expression profiles (n =  232) from the Immunological Genome Project
were downloaded on 7/22/14 from the GEO database under the accession number GSE1590724. Human
immune lineage gene expression profiles were downloaded from the GEO database under the accession
number GSE24006 (Gentles et al., n =  8)19 and GSE24759 (Novershtern et al., n =  38)34. For the willm00119 and GSE15907 datasets (.CEL files), the data was background corrected using Robust Microarray
Analysis (RMA), quantile normalized, and fitted with a multichip linear model for each probeset. These
techniques were carried out using the “expresso” function of the “affy” library in R35. GSE12417, which
contained gene expression measurements from the GPL96, GPL97, and GPL570 platforms, was represented by the probeset overlap between GPL96 and GPL570. For all datasets, probeset expression was
converted into gene expression. Genes with multiple probesets were represented by the probeset with
the highest average intensity across all samples. Murine transcripts were matched to human transcripts
on the basis of gene symbol.
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Pre-processing of hematopoietic cell profiles. To calculate the LSS, the BASE algorithm25 requires

that hematopoietic cell expression profiles be normalized to reflect the relative expression of each gene
in a given cell type. This process can be broken into five steps: (i) Gene expression values in the dataset
containing murine or human hematopoietic profiles (GSE15907, GSE24006, or GSE24759) are median
normalized across cell types to transform absolute expression values into relative expression values. As a
result, genes that are more highly expressed in a given cell type relative to the other cell types will have a
higher expression value. (ii) Each cell type’s median-normalized values are then z-transformed, causing
each cell type’s expression values to follow a standard normal distribution (~N(0,1)). Z-scores >  0 indicate genes that are up-regulated in a given cell type relative to the other cell types in the dataset, while
z-scores <  0 indicate the opposite. In some cases, datasets may contain replicate gene expression experiments representing the same cell type that need to be combined into a single column. These replicates
are collapsed during this step, using the mean z-score of each replicate and then each cell type’s values
are z-transformed again to renormalize. (iii) Each cell type’s resulting z-scores are then transformed into
up- and down-regulated subsets. In the up-regulated subset, z-scores >  0 maintain their value, while
z-scores <  0 are converted to 0, while the opposite is done in the down-regulated subset. This process
allows for the transformation of z-scores into p-values without losing the relative expression information
contained in the z-scores. (iv) The p-values are then –log10 transformed to place greater weight on differentially expressed genes. Outliers defined as transformed values >  10 are then trimmed to a maximum
of 10. (v) The resulting values are then scaled to values between 0 and 1 by dividing each value by the
maximum value in the overall dataset.

Calculation of the LSS.

To calculate the LSS, the BASE algorithm is inputted with the transformed
hematopoietic cell profiles and patient gene expression data. The up- and down-regulated subsets of each
hematopoietic cell type’s transformed values are defined as a weight vector W =  [w1, w2, w3…wj…wn];
where wj =   − log10(p-val) for gene j in that cell lineage and n =  # of genes. Patient gene expression data
is then processed based on the microarray platform. Gene expression values from two-channel arrays
require no additional processing, but one-channel arrays must first be log-transformed and median
normalized across samples, so that each gene expression value will reflect relative expression between
patients. Each patient’s gene expression profile is then treated as the vector g =  [g1, g2, g3…gj…gn], which
contains sorted (decreasing) gene expression values for each gene gj. Using these vectors, the BASE
algorithm calculates a “pre-LSS” for the “up” (pLSSup) and “down” (pLSSdn) lineage subsets through the
following steps:
First, a foreground function (f(i)) is used to calculate the cumulative distribution of the gene expression values for each patient weighted by their corresponding transformed hematopoietic relative expression values:

f (i ) =

i
∑ j= 1|g j w j|
n

∑ j= 1|g j w j|

,1≤i≤n

(1)

Second, a background function (b(i)) is used to calculate the cumulative distribution of the gene expression values for each patient weighted by a value complementary to the transformed hematopoietic relative expression values:

b (i ) =

i
∑ j= 1|g j (1 − w j)|
n
∑ j= 1|g j (1 − w j)|

,1≤i≤n

(2)

The maximum deviation of these two functions can then be compared to determine the pLSSup and
pLSSdn. This deviation is calculated by subtracting the foreground function from the background function and taking the difference with the largest absolute value. This requires comparing the maximum difference when the foreground function is larger than the background function (pLSS+) to the minimum
difference when the background function is larger than the foreground function (pLSS−). This process
is performed for both the up- and down-regulated subsets of each hematopoietic cell type. This step is
formulized below:
+
pLSSup
/ dn = max [f (i max ) − b (i max ), 0], where i max = arg max i = 1,2,3...n [ f (i ) − b (i ) ]

(3)

−
pLSSup
/ dn = min[f (i min) − b (i min), 0], where i min = arg min i = 1,2,3...n [f (i ) − b (i ) ]

(4)


 pLSS +, pLSS + > pLSS −
pLSS up/ dn = 

−


 pLSS , otherwise

(5)
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In the case of the up-regulated hematopoietic subset, a hematopoietic cell type that is highly similar to
a patient gene expression profile will cause the foreground function to increase quickly in the beginning, as highly expressed patient genes are assigned high hematopoietic weights, before plateauing
towards the end, as lowly expressed patient genes are assigned low weights. The background function
will increase slowly at the beginning, as lowly expressed genes are assigned low complementary weights,
before increasing quickly at the end. In the case of the down-regulated hematopoietic subset, where
higher weights correspond to more lowly expressed hematopoietic genes, the foreground function will
behave like the background function did in the up-regulated set and vice versa. As a result, in the case
of a highly similar patient profile and hematopoietic cell type, there will be a high deviation between the
foreground and background functions for both the up-regulated and down-regulated subsets, resulting
in a high pLSSup and pLSSdn. In the case of low similarity between the patient gene expression profile
and hematopoietic profile, both the foreground and background functions will be expected to increase
randomly, which would result in a low maximum deviation between the two functions, and thus a low
pLSSup and pLSSdn.
After the pLSSup and pLSSdn are calculated they are then normalized to their respective null distributions. The null distribution is generated by permuting the gene labels in the patient ranked gene list
1000 times and recalculating the pLSSup or pLSSdn for each permutation using equations 1–5. The pLSSup
and pLSSdn are then divided by the mean of the absolute value of the permuted values to yield the LSSup
and LSSdn. For datasets derived from two-channel arrays, the final LSS was obtained by subtracting LSSdn
from LSSup. For one-channel array datasets, which measure absolute mRNA expression, the LSSup served
as the final LSS, as the LSSdn was enriched in genes whose low expression values were obscured by noise
from nonspecific cross hybridization.

Survival analyses. Univariate Cox PH models were fitted to the LSSs for each lineage across all samples

in a dataset to investigate the relationship between LSS and survival time. For survival-associated LSSs,
multivariate Cox PH models incorporating FAB subtype, FLT3 mutation status, age, CALGB cytogenetic
risk36, and history of preceding malignancy were additionally constructed. Significance of the model
parameters was assessed using the Wald test and p-values were adjusted using the Benjamini-Hochberg
procedure. Kaplan-Meier curves were used to visualize the results, with samples stratified into two groups
based on their LSS scores: LSSs that were distributed bimodally were dichotomized about the local minima between the two peaks, otherwise, samples were dichotomized about their modal frequency. A
log-rank test was used to estimate the significance of the difference between the survival curves.
Survival analyses were performed in R using the “survival” package’s “coxph”, “survfit”, and “survdiff ”
functions for Cox PH modeling, Kaplan-Meier plotting, and log-rank significance testing, respectively.
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